Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3822.36% is 110% below its 3-year average of -1822.15%, around the middle of its 3-year range (-8923.98%–-731.24%).
6.29% below its 12-month average of -3596.01%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1116.13%.
EBITDA MARGIN
-3822.36%
EBITDA MARGIN AVG TTM
-3596.01%
EBITDA MARGIN AVG 3Y
-1762.77%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-6.29%
CURRENT VS 3Y AVG
-116.84%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Mangoceuticals, Inc.
Market Cap
$7.64M
EBITDA Margin
-3822.36%
TTM Avg
-3596.01%
3Y Avg
-1762.77%
5Y Avg
N/A
Market Cap
$7.67M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$7.87M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$7.92M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$8.04M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$8.05M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.64M | -3822.36% | -3596.01% | -1762.77% | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.29% | -74.83% | -125.41% | -344.12% |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | -334.15% | -180.95% | -121.99% | -121.99% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | N/A | N/A | N/A | N/A |
Gross Margin
54.4%
EBITDA Margin
-3822.4%
Operating Margin
-4200.5%
Net Margin
-4791.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1116.13% |
| 2026-03-31 | -4198.86% |
| 2025-12-31 | -1104.52% |
| 2025-09-30 | -8923.98% |
| 2025-06-30 | -2636.54% |
| 2025-03-31 | -4060.34% |
| 2024-12-31 | -908.54% |
| 2024-09-30 | -1317.97% |
| 2024-06-30 | -1309.23% |
| 2024-03-31 | -1102.97% |
| 2023-12-31 | -1048.29% |
| 2023-09-30 | -731.24% |
| 2023-06-30 | -1618.58% |
| 2023-03-31 | -2534.74% |
| 2022-12-31 | -7472.78% |
